In Clinical Leader Q&A, Simone Colgan Dunlap, Meghan O’Connor Outline Key Considerations When Selecting AI Vendor for Clinical Research
Quarles & Brady partners Simone Colgan Dunlap and Meghan O’Connor discussed the various factors that should be considered when preparing to select an artificial intelligence (AI) vendor for clinical research in a Q&A with Clinical Leader.
Colgan Dunlap is national vice chair of the firm’s Health & Life Sciences Practice Group and O’Connor is co-chair of the Artificial Intelligence and Data Asset Management, Privacy & Cybersecurity teams.
In the Q&A, they discuss topics such as the steps a company should take before contacting a potential vendor, the risks of contracting with an AI vendor, the data privacy, sharing and ownership rules that need to be in place, and more. An excerpt:
Choosing the right AI vendor for clinical research is a complex, high-stakes process requiring expert oversight from legal, clinical, IT, and privacy leaders. In this conversation, Meghan O’Connor, an attorney specializing in healthcare privacy and AI regulation, and Simone Colgan Dunlap, an advisor with deep experience in clinical data governance and technology strategy, unpack the must-know terminology, foundational diligence, and regulatory expectations organizations should master before partnering with an AI technology provider.
In this Q&A, Colgan Dunlap and O’Connor offer actionable guidance to help sponsor companies make informed, strategic choices in an evolving AI market.